Eiger BioPharmaceuticals, Inc. announced that Charles J. Bramlage notified the Board of Directors of the company of his resignation as a director effective immediately. Mr. Bramlage's resignation was not the result of any disagreement or dispute with the company on any matter relating to the company's operations, policies or practices. Effective January 3, 2018, the board appointed David Apelian, M.D., Ph.D., as the company's Chief Operating Officer and Executive Medical Officer, in addition to Dr. Apelian's role as a member of the Board. On January 5, 2018, upon recommendation of the Nominating and Corporate Governance Committee of the Board, the Board appointed Eldon Mayer as a director, effective as of January 5, 2018. The Board appointed Mr. Mayer to serve as a member of the Board as a Class III director for a term expiring at the Company’s 2018 Annual Meeting of Stockholders, or until his earlier death, resignation or removal or his successor is duly elected and qualified.